Positive News SentimentPositive NewsNASDAQ:NBP Novabridge Biosciences (NBP) Stock Price, News & Analysis $0.82 +0.03 (+3.89%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$0.84 +0.01 (+1.67%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Novabridge Biosciences Stock (NASDAQ:NBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novabridge Biosciences alerts:Sign Up Key Stats Today's Range$0.75▼$0.8350-Day Range$0.79▼$1.7052-Week Range$0.75▼$5.19Volume858,490 shsAverage Volume550,099 shsMarket Capitalization$95.39 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingHold Company Overview Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival. The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets. These products remain in clinical development and are not necessarily approved for commercial use. Novabridge Biosciences was founded in 2016 and historically maintained operations and development activities in both China and the United States. The company has since emphasized a more globally oriented, U.S.-focused development strategy while continuing to advance selected oncology programs through clinical studies and potential strategic partnerships. Dr. Joan Shen, a biopharmaceutical executive and physician, is the company’s founder and has served in senior leadership roles. AI Generated. May Contain Errors. Read More Novabridge Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreNBP MarketRank™: 2.8767671379 of 5 starsNovabridge Biosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 465th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingNovabridge Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialNovabridge Biosciences has a consensus price target of $9.00, representing about 994.5% upside from its current price of $0.82.Amount of Analyst CoverageNovabridge Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Novabridge Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Novabridge Biosciences are expected to decrease in the coming year, from ($0.54) to ($0.99) per share.Price to Book Value per Share RatioNovabridge Biosciences has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.96% of the float of Novabridge Biosciences has been sold short.Short Interest Ratio / Days to CoverNovabridge Biosciences has a short interest ratio ("days to cover") of 6.89.Change versus previous monthShort interest in Novabridge Biosciences has recently decreased by 3.29%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovabridge Biosciences does not currently pay a dividend.Dividend GrowthNovabridge Biosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentNovabridge Biosciences has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Novabridge Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $88,325.00 in company stock.Percentage Held by Insiders22.10% of the stock of Novabridge Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions38.38% of the stock of Novabridge Biosciences is held by institutions.Read more about Novabridge Biosciences' insider trading history. Receive NBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novabridge Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBP Stock News HeadlinesVisara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD1 hour ago | globenewswire.comNovaBridge Biosciences to Participate in Upcoming Investor ConferencesNovember 9, 2026 | finance.yahoo.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 18 at 1:00 AM | Porter & Company (Ad)Financial Review: Xenon Pharmaceuticals (NASDAQ:XENE) vs. Novabridge Biosciences (NASDAQ:NBP)November 7, 2026 | americanbankingnews.comBrokers Offer Predictions for NBP FY2026 EarningsNovember 7, 2026 | americanbankingnews.comNovaBridge Biosciences (NBP) Stock Forecast & Price TargetNovember 4, 2026 | tipranks.comNovaBridge Biosciences (NBP) Discusses Mature Givastomig Data and Registrational Development Strategy TranscriptNovember 2, 2026 | seekingalpha.comNovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial OfficerOctober 28, 2026 | globenewswire.comSee More Headlines NBP Stock Analysis - Frequently Asked Questions How have NBP shares performed this year? Novabridge Biosciences' stock was trading at $3.70 on February 6, 2026. Since then, NBP shares have decreased by 77.8% and is now trading at $0.8223. How were Novabridge Biosciences' earnings last quarter? Novabridge Biosciences (NASDAQ:NBP) posted its quarterly earnings results on Thursday, August, 20th. The company reported ($0.16) EPS for the quarter. Who are Novabridge Biosciences' major shareholders? Top institutional investors of Novabridge Biosciences include Marshall Wace LLP (0.63%), State Street Corp (0.27%) and Goldman Sachs Group Inc. (0.11%). Insiders that own company stock include Cong Claire Xu, Sean Wuxiong Cao, Mark Arnold Hagler and Phillip Andrew Dennis. View institutional ownership trends. How do I buy shares of Novabridge Biosciences? Shares of NBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/20/2026Today11/17/20269th Annual Evercore ISI HealthCONx Conference11/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NBP's financial health is in the Red zone, according to TradeSmith. NBP has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NBP CIK1778016 Webwww.novabridge.com Phone(301) 670-2800FaxN/AEmployees30Year Founded2016Price Target and Rating Average Price Target for Novabridge Biosciences$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+994.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.64 Quick RatioN/A Sales & Book Value Annual Sales$3.89 million Price / Sales24.52 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book0.41Miscellaneous Outstanding Shares116,000,000Free Float90,363,000Market Cap$95.39 million OptionableOptionable Beta1.70 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:NBP) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novabridge Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Novabridge Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.